AbbVie (ABBV) Tops Q4 EPS by 3c, Confirms Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
AbbVie (ABBV) PT Trimmed at Jefferies But Sees Excellent Entry Point
February 3, 2015 8:41 AM ESTJefferies analyst Jeffrey Holford reiterated a Buy rating on Abbvie (NYSE: ABBV) following Q4 results but lowered his price target to $80.00 (from $82.00). The firm said recent weakness creates an excellent entry point.
Holford commented, "We view ABBV's 2015 HCV guidance as conservative, which is... More
